Yanqiu Zhao

An epidermal growth factor receptor-mutated lung adenocarcinoma patient with brain lesions resisted to osimertinib monotherapy but achieved more than 4 years of survival in osimertinib plus bevacizumab metronomic treatment

Jie Liu, Xiu-feng Hu, Kai Wang, 2024, Heliyon.

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial.

Dingzhi Huang, S. Leaw, Xingya Li, 2024, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial.

H. Yue, N. Yang, Yingying Du, 2024, The Lancet. Respiratory medicine.

Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment: A phase 2 clinical trial (BG01-1801)

Gongyan Chen, Jing-Min Zhao, Yuankai Shi, 2023, Cancer pathogenesis and therapy.

A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib

Jianya Zhou, W. Dong, Qitao Yu, 2024, Therapeutic advances in medical oncology.

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study

W. Feng, K. Ma, G. Selvaggi, 2024, Cancer communications.